13F Insight
DOSSIER · 13F-HR · Q1 2026

venBio Partners LLC

$281M in tracked AUM across 6 positions as of Q1 2026.

VP
CIK 0001776382 · last filed Mar 31, 2026
Total AUM
$281M
as of Q1 2026
Holdings
6
—
positions
Whale Score
69
69
tracked
Activity
—
no data
changes this Q
AI Analysis · Q1 2026

Portfolio Overview

venBio Partners LLC presents a highly concentrated, high-conviction investment portfolio as of the reporting period September 30, 2025. The firm manages approximately $144.49 million in assets across a mere four holdings, signaling a strategy focused on deep specialization rather than broad diversification. The portfolio experienced significant growth during the quarter, increasing in value by 25.9% from $114.76 million. This appreciation is a result of a combination of c...

Key Holdings

The portfolio is dominated by PHARVARIS N V, which stands as the cornerstone position with a market value of $115.75 million. This single position comprises 80.11% of the entire portfolio, consisting of 4.64 million shares. The firm increased its stake in Pharvaris by 8.2% during the quarter, adding $40.26 million in value, which underscores a strong conviction in the company’s prospects despite the already massive concentration.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
N69605108
PHARVARIS N V
$131M4.6M46.7%02
ALMS
ALUMIS INC
$100M4.5M35.6%03
ALXO
ALX ONCOLOGY HLDGS INC
$26M12.9M9.2%04
HRMY
HARMONY BIOSCIENCES HLDGS IN
$14M489K4.9%05
LYEL
LYELL IMMUNOPHARMA INC
$7M338K2.4%06
ARTV
ARTIVA BIOTHERAPEUTICS INC
$3M531K1.2%

Filing history

2026Q1Mar 31
$281M▲ 29.7%
6 positionsView →2025Q4Dec 31
$216M▲ 49.7%
6 positionsView →2025Q3Sep 30
$144M▲ 25.9%
4 positionsView →2025Q2Jun 30
$115M▲ 27.2%
6 positionsLocked2025Q1Mar 31
$90M▼ 47.2%
5 positionsLocked2024Q4Dec 31
$171M▼ 12.2%
7 positionsLocked2024Q3Sep 30
$194M▼ 16.1%
6 positionsLocked2024Q2Jun 30
$232M▼ 17.9%
6 positionsLocked2024Q1Mar 31
$282M▼ 57.8%
5 positionsLocked2023Q4Dec 31
$667M▲ 89.2%
7 positionsLocked2023Q3Sep 30
$353M▲ 27.6%
8 positionsLocked2023Q2Jun 30
$276M▲ 53.1%
7 positionsLocked
Showing 12 of 30